![Magnus Nylén](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Magnus Nylén
Directeur/Bestuurslid bij
SELECTIMMUNE PHARMA AB (PUBL)
Profiel
Magnus Nylén is currently Director at Hamlet BioPharma AB starting in 2025.
Mr. Nylén is also Director at SelectImmune Pharma AB since 2022.
Additionally, Mr. Nylén has been Owner at Partner Fondkommission AB since 2013.
Mr. Nylén completed undergraduate education at Boston University.
Actieve functies van Magnus Nylén
| Bedrijven | Functie | Begin |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Directeur/Bestuurslid | 23-11-2022 |
| HAMLET PHARMA AB (PUBL) | Directeur/Bestuurslid | 11-03-2025 |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Magnus Nylén
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
6
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Finance |
Hamlet BioPharma AB
 Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
SelectImmune Pharma AB
 SelectImmune Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops and manufactures immune enhancers to complement antibiotics | Health Technology |
